Collaborative Research on New Drugs for the Treatment of Tuberculosis and Malaria
Astellas is pursuing collaborative research to discover new drugs for the treatment of tuberculosis and malaria, which are infectious diseases that cause tremendous suffering among people in developing countries.
In 2019 10 million incidences of tuberculosis were observed with 1.4 million* deaths, and more than 200 million incidences of malaria were observed with 409,000 deaths. Both tuberculosis and malaria have led to serious social problems, underscoring the urgent need for innovative drugs to treat these diseases.
<Discovery of New Tuberculosis Drugs (“TB drugs”)>
Astellas has conducted joint research (“Screening PJ”) for exploration of new compounds for Mycobacterium tuberculosis in collaboration with TB Alliance since October 2017. The hit compounds on hand appear to be unique in their structures compared with TB drugs in use or under development. They also appear not to share the mechanism of action with the existing TB drugs suggesting activity against drug-resistant strains of Mycobacterium tuberculosis. Astellas and TB Alliance entered into a new collaborative research agreement on March 31, 2021 to identify lead compounds with improved pharmacological activity pharmacokinetics, and safety by utilizing multiple hit compounds obtained from the Screening PJ.
Considering these backgrounds, in October 2017, Astellas entered into a new collaborative research agreement with TB Alliance for the exploration of new drugs for the treatment of tuberculosis and a screening collaboration agreement with Medicines for Malaria Venture (MMV) to discover new drugs for malaria.
<Discovery of New Antimalarial Drugs>
Astellas entered into a collaborative research agreement with MMV, for the exploration of antimalarial drug in October, 2017. Under this agreement, Astellas has provided its original library of tens of thousands of compounds, and MMV has worked to screen the library for compounds that demonstrate the potential to become new antimalarial drugs.
These research programs are funded by the Global Health Innovative Technology Fund (“GHIT Fund”).
*Figure includes 0.208 million people infected with HIV.